6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Items 401–500 of 793
Continuous flow synthesis and scale-up of glycine- and taurine-conjugated bile salts
Venturoni, F., Gioiello, A., Sardella, R., Natalini, B., & Pellicciari, R. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob25528f · Cited by 26
Self-citationFu, J., Si, P., Zheng, M., Chen, L., Shen, X., Tang, Y., & Li, W. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.09.045 · Cited by 24
Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR)
Costantino, G., Macchiarulo, A., Entrena-Guadix, A., Camaioni, E., & Pellicciari, R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00281-6 · Cited by 24
Self-citationSteroidal or non-steroidal FXR agonists – Is that the question?
Verbeke, L., Nevens, F., & Laleman, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.013 · Cited by 25
Fiorucci, S., Sepe, V., Biagioli, M., Fiorillo, B., Rapacciuolo, P., Distrutti, E., & Zampella, A. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115776 · Cited by 23
Self-citationTølbøl, K. S., Stierstorfer, B., Rippmann, J. F., Veidal, S. S., Rigbolt, K. T. G., Schönberger, T., Gillum, M. P., Hansen, H. H., Vrang, N., Jelsing, J., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5395-7 · Cited by 24
Gao, Y., Lin, J., Ye, C., Guo, S., & Jiang, C. (2023) · Liver Research · doi:10.1016/j.livres.2023.09.002 · Cited by 36
Pharmacotherapy of cholestatic liver diseases
Paumgartner, G. (2010) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00427.x · Cited by 26
Chemical and metabolic transformations of selected bile acids
Kuhajda, K., Kevrešan, S., Kandrač, J., Fawcett, J. P., & Mikov, M. (2006) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190713 · Cited by 22
Diagnosis and management of primary biliary cirrhosis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.979792 · Cited by 24
Yu, D. D., Mattern, D. L., & FORMAN, B. M. (2012) · Steroids · doi:10.1016/j.steroids.2012.09.002 · Cited by 22
Targeting the FXR Nuclear Receptor to Treat Liver Disease
Neuschwander‐Tetri, B. A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.037 · Cited by 25
Tawfiq, R. A., Nassar, N. N., Hammam, O. A., Allam, R. M., Elmazar, M. M., Abdallah, D. M., & Attia, Y. M. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109953 · Cited by 21
Fuchs, C. D., SRODA, N., Scharnagl, H., Gupta, R. S., Minto, W. C., Stojaković, T., Liles, J. T., Budas, G. R., Hollenback, D., & Trauner, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100874 · Cited by 24
“6,7 Based on these fi ndings clinical trials of OCA in patients with primary biliary cholangitis (PBC) or PSC were conducted, 8 – 11 with OCA gaining approval for PBC.”
BackgroundAmorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 25
Cheng, Q., Inaba, Y., Lu, P., Xu, M., He, J., Zhao, Y., Guo, G. L., Kuruba, R., de la Vega, R., Evans, R. G., et al. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1337 · Cited by 22
Recent Advances in Non-Steroidal FXR Antagonists Development for Therapeutic Applications
Huang, H., Xu, Y., Zhu, J., & Li, J. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666141112101840 · Cited by 22
Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR
Lee, J. M. (2016) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2016.21.4.193 · Cited by 22
Huang, H., Si, P., Wang, L., Xu, Y., Xu, X., Zhu, J., Jiang, H., Li, W., Chen, L., & Li, J. (2015) · ChemMedChem · doi:10.1002/cmdc.201500136 · Cited by 23
Zhu, Y., Xu, S., Lu, Y., Wei, Y., Yao, B., Guo, F., Zheng, X., Wang, Y., He, Y., Jin, L., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00590 · Cited by 21
“With the development of obeticholic acid (OCA) (Pellicciari et al., 2002), a semisynthetic bile acid analogue and a ligand for FXR, in clinical trials for NASH, FXR has emerged as an attractive drug target for NAFLD.”
BackgroundLi, Y., Wang, K., Ding, J., Sun, S., Ni, Z., & Yu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.954684 · Cited by 23
“6-Alpha-ethyl-chenodeoxycholic acid (OCA), which was first discovered while studying FXR receptor ligands, is obtained by adding an ethyl group to the 6-position of the benzene ring of CDCA and has improved physicochemical properties (Pellicciari et al., 2002).”
BackgroundSome non-conventional biomolecular targets for diamidines. A short survey
Huang, T. L., Mayence, A., & Eynde, J. J. V. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.049 · Cited by 21
Liu, P., Xu, X. Y., Chen, L., Ma, L., Shen, X., & Hu, L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.01.032 · Cited by 22
Olthof, P. B., Huisman, F., Schaap, F. G., van Lienden, K. P., Bennink, R. J., van Golen, R. F., Heger, M., Verheij, J., Jansen, P. L. M., Damink, S. W. M. O., et al. (2017) · British journal of surgery · doi:10.1002/bjs.10466 · Cited by 20
Gerussi, A., D’Amato, D., Cristoferi, L., O’Donnell, S. E., Carbone, M., & Invernizzi, P. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.09.009 · Cited by 22
Marchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Morretta, E., Monti, M. C., Distrutti, E., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202101397r · Cited by 21
Self-citationStructure–activity relationship of bile alcohols as human farnesoid X receptor agonist
Iguchi, Y., Kihira, K., Nishimaki‐Mogami, T., & Une, M. (2009) · Steroids · doi:10.1016/j.steroids.2009.11.002 · Cited by 20
Bile acid‐activated receptors in innate and adaptive immunity: targeted drugs and biological agents
Cheung, K. C. P., Ma, J., Loiola, R. A., Chen, X., & Jia, W. P. (2023) · European Journal of Immunology · doi:10.1002/eji.202250299 · Cited by 24
Parés, A. R., Shiffman, M. L., Vargas, V., Invernizzi, P., Malecha, E. S., Liberman, A., MacConell, L., & Hirschfield, G. M. (2020) · Liver International · doi:10.1111/liv.14429 · Cited by 21
Štefela, A., Kašpar, M., Drastík, M., Kronenberger, T., Mičuda, S., Dračínský, M., Klepetářová, B., Kudová, E., & Pávek, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713149 · Cited by 21
“On the other hand, after the discovery of obeticholic acid (6αethyl-chenodeoxycholic acid, OCA, INT-747), the first-in-class FXR ligand (Pellicciari et al., 2002) approved for the treatment of resistant primary biliary cholangitis (PBC), the structural modifications of BAs have been intensively focused on the developm…”
BackgroundFXR/ASS1 axis attenuates the TAA-induced liver injury through arginine metabolism
Hong, W., Peng, X., Zhou, X., Li, P., Ye, Z., & Liang, W. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.073 · Cited by 21
Current and future treatment for alcoholic‐related liver diseases
Yoon, E. L., & Kim, W. K. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16257 · Cited by 22
Flesch, D., Gabler, M., Lill, A., Gomez, R. C., Steri, R., Schneider, G., Stark, H., Schubert‐Zsilavecz, M., & Merk, D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.035 · Cited by 21
Treatment options for primary sclerosing cholangitis
Sinakos, E., & Lindor, K. D. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.33 · Cited by 20
Farnesoid X receptor: a potential therapeutic target in multiple organs.
Zhang, C., Wang, Z., Feng, Q., Chen, W., & Wang, Y. (2020) · PubMed · doi:10.14670/hh-18-301 · Cited by 19
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
“Obeticholic acid (OCA), a 6 α -ethyl derivate of chenodeoxycholic acid, represents the first FXR agonist and efficiently activates FXR [185,186].”
Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
Mahtab, M. A., Akbar, S. M. F., Roy, P. P., Rahim, M. A., Yesmin, S. M. S., & Islam, S. B. (2022) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1360 · Cited by 18
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis
Ronca, V., Carbone, M., Bernuzzi, F., Malinverno, F., Mousa, H. S., Gershwin, M. E., & Invernizzi, P. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1391093 · Cited by 18
New therapies target the toxic consequences of cholestatic liver disease
Jansen, P. L. M. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1424538 · Cited by 19
“Obeticholic acid (INT-747, 6αethyl-chenodeoxycholic acid) is a semisynthetic compound with a 100 times higher binding affinity for FXR than natural bile salts [8,9].”
BackgroundSelective Optimization of Pranlukast to Farnesoid X Receptor Modulators
Schierle, S., Schmidt, J., Kaiser, A., & Merk, D. (2018) · ChemMedChem · doi:10.1002/cmdc.201800549 · Cited by 18
Emerging novel treatments for autoimmune liver diseases
Tanaka, A. (2019) · Hepatology Research · doi:10.1111/hepr.13347 · Cited by 19
Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast
Schierle, S., Helmstädter, M., Schmidt, J., Hartmann, M., Horz, M., Kaiser, A., Weizel, L., Heitel, P., Proschak, A., Hernández‐Olmos, V., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900576 · Cited by 19
Wang, B., Zhang, H., Luan, Z., Xu, H., Wei, Y., Zhao, X., Xing, M., Huo, X., Zhang, J., Su, W., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111949 · Cited by 19
Roda, A., Aldini, R., Camborata, C., Spinozzi, S., Franco, P., Cont, M., D’Errico, A., Vasuri, F., Degiovanni, A., Maroni, L., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12468 · Cited by 19
Biologically active metabolites in drug discovery
Sun, S., & Wesolowski, S. S. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128255 · Cited by 19
Use of human tissue stem cell-derived organoid cultures to model enterohepatic circulation
Blutt, S. E., Crawford, S. E., Bomidi, C., Zeng, X., Broughman, J. R., Robertson, M. J., Coarfa, C., Tessier, M. E. M., Savidge, T., Hollinger, F. B., et al. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00177.2021 · Cited by 18
Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
Lin, C., Yu, B., Chen, L., Zhang, Z., Ye, W., Zhong, H., Bai, W., Yang, Y., & Nie, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.880508 · Cited by 24
Corner, T. P., Teo, R. Z. R., Wu, Y., Salah, E., Nakashima, Y., Fiorini, G., Tumber, A., Brasnett, A., Holt‐Martyn, J. P., Figg, W. D., et al. (2023) · Chemical Science · doi:10.1039/d3sc04253g · Cited by 19
Evolving therapies for non-alcoholic steatohepatitis
Tilg, H., & Moschen, A. R. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.911283 · Cited by 18
“OCA has also been characterized as an anticholestatic and hepatoprotective agent [73].”
BackgroundMorelli, A., Vignozzi, L., Maggi, M., & Adorini, L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.10.013 · Cited by 19
“The semi-synthetic chenodeoxycholic acid derivative 6α-ethyl chenodeoxycholic acid (INT-747, obeticholic acid) is a selective and potent FXR agonist originally described for its anti-cholestatic properties [68].”
BackgroundSelf-citationProteomics for the discovery of nuclear bile acid receptor FXR targets
Gardmo, C., Tamburro, A., Modica, S., & Moschetta, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.03.009 · Cited by 19
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 19
Primary biliary cirrhosis: From bench to bedside
Kouroumalis, E., & Notas, G. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.32 · Cited by 21
Obeticholic acid for the treatment of primary biliary cirrhosis
Jones, D. E. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1216784 · Cited by 18
Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
Diao, Y., Jiang, J., Zhang, S., Li, S., Shan, L., Huang, J. Y., Zhang, W., & Li, H. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00140 · Cited by 20
“Obeticholic acid (6αethyl-chenodeoxycholic acid, 6-ECDCA), a semi-synthetic bile acid analog with highly potent FXR agonistic activity (EC50 = 0.099µM) (Pellicciari et al., 2002), is the first FDA-approved drug that is used for treating primary biliary cholangitis (PBC) (Nevens et al., 2016).”
BackgroundLeva, F. S. D., Festa, C., Carino, A., Marino, S. D., Marchianò, S., Marino, D. D., Finamore, C., Monti, M. C., Zampella, A., Fiorucci, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38840-z · Cited by 20
Self-citationEmerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yang, Y., Zhao, Y., Li, W., Wu, Y., Wang, X., Wang, Y., Liu, T.-M., Ye, T., Xie, Y., Cheng, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112311 · Cited by 17
Improving glucose and lipids metabolism: drug development based on bile acid related targets
Shen, H., Ding, L., Baig, M., Tian, J., Wang, Y., & Huang, W. (2021) · Cell Stress · doi:10.15698/cst2021.01.239 · Cited by 20
Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
Zhang, F., Xiao, X., Li, Y., Wu, H., Deng, X., Jiang, Y., Zhang, W., Wang, J., Ma, X., & Zhao, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.805269 · Cited by 20
“The compound INT747, which was first developed in 2002, is a dual ligand of FXR and GPBAR1, but it caused a more intense itch response in clinical trials, so the benefits of this synergistic approach were not realized (Pellicciari et al., 2002).”
BackgroundNavigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands
Finamore, C., Festa, C., Renga, B., Sepe, V., Carino, A., Masullo, D., Biagioli, M., Marchianò, S., Capolupo, A., Monti, M. C., et al. (2016) · Scientific Reports · doi:10.1038/srep29320 · Cited by 19
“Indeed, results from PBC phase II clinical trial with 6-ECDCA/OCA ( 3 ), a potent semi-synthetic steroidal FXR agonist 27 , have shown that while the compound exerts benefit, its use has associated with pruritus.”
Self-citationPereira-Fantini, P. M., Lapthorne, S., Gahan, C. G. M., Joyce, S. A., Charles, J., Fuller, P. J., & Bines, J. E. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.02.008 · Cited by 17
Qiu, R., Luo, G., Cai, X., Liu, L., Chen, M., Chen, D., You, Q., & Xiang, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.021 · Cited by 17
Etherington, R. E., Millar, B. J. M., Innes, B. A., Jones, D. E., Kirby, J. A., & Brain, J. G. (2019) · FASEB BioAdvances · doi:10.1096/fba.2018-00046 · Cited by 16
He, X., Shi, J., Bu, L., Zhou, S., Wu, K., Liang, G., Xu, X., & Wang, A.-Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116574 · Cited by 20
Comeglio, P., Filippi, S., Sarchielli, E., Morelli, A., Cellai, I., Corno, C., Adorini, L., Vannelli, G. B., Maggi, M., & Vignozzi, L. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-1009-2 · Cited by 18
Self-citationEl‐Shoura, E. A. M., Hassanein, E. H. M., Taha, H. H., Shalkami, A. S., Hassanein, M. M. H., Ali, F. E. M., & Bakr, A. G. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-02956-5 · Cited by 16
“Previous studies reported that OCA and its derivatives had been shown to decrease the release of proinflammatory cytokines in osteoarthritis and acute liver failure (Guo et al. 2021; Pellicciari et al. 2002).”
Rapacciuolo, P., Finamore, C., Giorgio, C. D., Fiorillo, B., Massa, C., Urbani, G., Marchianò, S., Bordoni, M., Cassiano, C., Morretta, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01651 · Cited by 17
Self-citationBiological functions and pharmacological behaviors of bile acids in metabolic diseases
Zhuang, T., Wang, X., Wang, Z., Gu, L., Yue, D., Wang, Z., Li, X., Yang, L., Huang, W., & Ding, L. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.11.003 · Cited by 29
“INT-767 interacts with both receptors [129–131].”
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 17
“Obeticholic acid has similar potency in functional assays with a reported EC50 w90 nM, which is nearly 100-fold more potent than its natural bile acid precursor [60].”
BackgroundObeticholic Acid Derivative, T-2054 Suppresses Osteoarthritis via Inhibiting NF-κB-Signaling Pathway
Guo, D., He, L., Gao, Y., Jin, C., Lin, H., Zhang, L., Wang, L., Zhou, Y. Y., Yao, J., Duan, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083807 · Cited by 16
“Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, prevented mice from LPS-induced liver injury, ameliorated liver injury induced by carbon tetrachloride via inhibiting inflammatory activity and alleviated the symptoms of acute liver injury [4,17,20].”
BackgroundTranscriptional Regulation of Hepatic Autophagy by Nuclear Receptors
Kim, E. Y., & Lee, J. M. (2022) · Cells · doi:10.3390/cells11040620 · Cited by 18
Merk, D., Steinhilber, D., & Schubert‐Zsilavecz, M. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.860129 · Cited by 16
“6-ECDCA Coactivator recruitment (FRET) EC50 = 99 nM (144% of CDCA) [17]”
BackgroundMethodInfluentialBile acid receptors link nutrient sensing to metabolic regulation
Li, J., & Li, T. (2017) · Liver Research · doi:10.1016/j.livres.2017.04.001 · Cited by 21
FXR-targeted drug discovery: Recent advances and therapeutic perspectives
Li, Q., Liu, Z., Shang, W., Zhou, X., Mao, W., Cao, Y., & Shan, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118332 · Cited by 19
Differential roles of farnesoid X receptor (FXR) in modulating apoptosis in cancer cells
Girisa, S., Rana, V., Parama, D., Dutta, U., & Kunnumakkara, A. B. (2021) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2021.02.006 · Cited by 16
Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse
Lin, C., Yu, B., Liu, X., Chen, L., Zhang, Z., Ye, W., Zhong, H., Bai, W., Yang, Y., & Nie, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112984 · Cited by 15
Marinozzi, M., Carotti, A., Sardella, R., Buonerba, F., Ianni, F., Natalini, B., Passeri, D., Rizzo, G., & Pellicciari, R. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.038 · Cited by 15
Self-citationSardella, R., Marinozzi, M., Ianni, F., Lisanti, A., & Natalini, B. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6348-1 · Cited by 15
Park, J., Al-Hilal, T. A., Jeong, J., Choi, J. U., & Byun, Y. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00230 · Cited by 15
A New FXR Ligand Chemotype with Agonist/Antagonist Switch
Helmstädter, M., Vietor, J., Sommer, J., Schierle, S., Willems, S., Kaiser, A., Schmidt, J., & Merk, D. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00647 · Cited by 15
Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
Jose, S., Devi, S. S., Sajeev, A., Girisa, S., Alqahtani, M. S., Abbas, M., Alshammari, A., Sethi, G., & Kunnumakkara, A. B. (2022) · Bioscience Reports · doi:10.1042/bsr20212791 · Cited by 15
Emerging drugs for non-alcoholic steatohepatitis
Tomeno, W., Yoneda, M., Imajo, K., Ogawa, Y., Kessoku, T., Saito, S., Eguchi, Y., & Nakajima, A. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.811232 · Cited by 18
“2 Obeticholic acid Obeticholic acid (OCA, also known as INT-747) is a 6aethyl derivative of chenodeoxycholic acid (CDCA) and is a first-in-class selective farnesoid X receptor (FXR) agonist that was originally described for its anticholestatic and potentially broader hepatoprotective properties [57].”
BackgroundEmerging pharmacologic therapies for primary sclerosing cholangitis
Cheung, A., Lazaridis, K. N., LaRusso, N. F., & Gores, G. J. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000352 · Cited by 17
Zhang, C., Gan, Y., Lv, J.-W., Qin, M.-Q., Hu, W., Liu, Z.-B., Ma, L., Song, B., Li, J., Jiang, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106442 · Cited by 15
Shah, R. A., Alkhouri, N., & Kowdley, K. V. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1796968 · Cited by 15
Trauner, M., & Boyer, J. L. (2003) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200305000-00005 · Cited by 16
Li, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15
Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 15
Shan, D., Dai, S., Chen, Q., Xie, Y., & Hu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1218432 · Cited by 16
Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole
Sai, M., Vietor, J., Kornmayer, M. M., Egner, M., López-García, Ú., Höfner, G. C., Pabel, J., Marschner, J. A., Wein, T., & Merk, D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00852 · Cited by 16
Elfaki, D., Bjornsson, E. S., & Lindor, K. D. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04104.x · Cited by 15
Gardès, C., Blum, D., Bleicher, K., Chaput, E., Ebeling, M., HARTMAN, P. G., Handschin, C., Richter, H. G., & Benson, G. M. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012542 · Cited by 14
Treatment of Non-Alcoholic Fatty Liver Disease
Scherer, A., & Dufour, J. (2016) · Digestive Diseases · doi:10.1159/000447278 · Cited by 16
Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica
Ampuero, J., Sanchez-Torrijos, Y. M., Aguilera, V., Bellido, F., & Romero‐Gómez, M. (2017) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.07.006 · Cited by 20
Shim, S., Krishnaiah, M., Sankham, M. R., Kim, I., Lee, Y., Shin, I., Oh, A., Lee, H. J., Vu, T. N. L., Park, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00641 · Cited by 14
Ebert, B., Kisiela, M., & Maser, E. (2016) · Drug Metabolism Reviews · doi:10.3109/03602532.2016.1167902 · Cited by 15
“Synthetic FXR ligands include the BA derivative 6-alpha-ethyl-chenodeoxycholic acid (Pellicciari et al., 2002) and the antiparasitic drug ivermectin (Jin et al., 2013).”
BackgroundHu, L., Ren, Q., Deng, L., Zhou, Z., Cai, Z., Wang, B., & Li, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113106 · Cited by 14
Bile Acid-Induced Liver Injury in Cholestasis
Li, T., & Chiang, J. Y. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-53774-0_7 · Cited by 16
Gay, M. D., Cao, H., Shivapurkar, N., Dakshanamurthy, S., Kallakury, B., Tucker, R. D., Kwagyan, J., & Smith, J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031899 · Cited by 14
Primary biliary cholangitis: primary autoimmune disease or primary secretory defect
Floreani, A., Gabbia, D., & Martin, S. D. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2242771 · Cited by 16
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.